ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting - Press Release
Trial Met Primary Endpoint with Confirmed Objective Response Rate of 32.4%, including 5 Complete Responses; Updated Median Duration of Response of 6.9
Source: wiredprnews.com